Browse studies
Find your next paid study
292 recruiting studies matching your filters
Phase 2
Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial
This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived…
Breast CancerSarcomaGastric Cancer+7 more
Estimated
~$10 – $6,250
University of California, IrvineNCT06580002
Phase 1
Phase I Clinical Trial of Allogeneic Bone Marrow Human Mesenchymal Stem Cells Loaded With A Tumor Selective Oncolytic Adenovirus, DNX-2401, Administered Via Intra-Arterial Injection in Patients With Recurrent High-Grade Glioma
This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurren…
IDH1 wt AlleleRecurrent Anaplastic AstrocytomaRecurrent Glioblastoma+2 more
Estimated
~$10 – $6,250
M.D. Anderson Cancer CenterNCT03896568
Phase 2
A Phase II Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
A phase 2 study assessing the efficacy of all-trans retinoic acid (ATRA) and Cemiplimab in patients with metastatic/locally advanced - unresectable leiomyosarc…
LeiomyosarcomaSarcoma
Estimated
~$10 – $7,500
Gabriel TinocoNCT06528769
Phase 1
An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination wi…
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more
Estimated
~$10 – $8,750
GI Innovation, Inc.NCT05824975